Safety and Efficacy of NK510 to Treat NSCLC

NCT06097962 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC

Interventions

DRUG: NK510
DRUG: Tislelizumab，atezolizumab or sugemalimab
DRUG: NK510
DRUG: systemic therapy as selected by the investigator

Sponsor

Base Therapeutics (Shanghai) Co., Ltd.

Collaborators

[object Object]